期刊文献+

FTY720对心血管系统的作用

下载PDF
导出
摘要 FTY720是一种新型免疫抑制剂,目前被广泛应用于器官移植及自身免疫性疾病的治疗。随着对1-磷酸鞘氨醇(S1P)在心血管疾病中作用研究的深入,FTY720作为S1P的结构类似物,其心血管效应也越来越受到关注。FTY720通过改善内皮通透性、抑制血管平滑肌细胞增殖、促细胞生存、抑制心肌纤维化等,在心血管系统中起保护作用。该文就FTY720在心血管方面的作用特点及其机制作一介绍。
作者 戴道鹏 陶蓉
出处 《国际心血管病杂志》 2014年第5期315-317,共3页 International Journal of Cardiovascular Disease
基金 国家自然科学基金(81370256)
  • 相关文献

参考文献18

  • 1Pitman MR,WoodcockJM,Lopez AF,etal.MoleculartargetsofFTY720 (fingolimod)[J].CurrMolMed,2012,12(10):1207-1219.
  • 2HlaT,BrinkmannV.Sphingosine1-phosphate(S1P):PhysiologyandtheeffectsofS1Preceptormodulation [J].Neurology,2011,76(8Suppl3):S3-S8.
  • 3GoldR,ComiG,PalaceJ,etal.Assessmentofcardiacsafetyduring fingolimod treatment initiation in a realworldrelapsing multiplesclerosispopulation:aphase3b,openlabelstudy[J].JNeurol,2014,261(2):267-276.
  • 4SchmouderR,HariryS,DavidOJ.Placebocontrolledstudyoftheeffectsoffingolimodoncardiacrateandrhythmandpulmonaryfunctionin healthyvolunteers [J].EurJClinPharmacol,2012,68(4):355-362.
  • 5CalabresiPA,RadueEW,Goodin D,etal.Safetyandefficacy offingolimodin patients withrelapsingremittingmultiple sclerosis (FREEDOMS Ⅱ ): a doubleblind,randomised,placebocontrolled,phase3trial[J].LancetNeurol,2014,13(6):545-556.
  • 6FryerRM,Muthukumarana A,HarrisonP C,etal.Theclinicallytested S1P receptor agonists, FTY720 andBAF312,demonstrate subtypespecific bradycardia (S1P(1))andhypertension (S1P (3))inrat [J].PLoS One,2012,7(12):e52985.
  • 7SpijkersLJ,AlewijnseAE,PetersSL.FTY720 (fingolimod)increasesvasculartoneandbloodpressureinspontaneouslyhypertensiveratsviainhibitionofsphingosinekinase[J].BrJPharmacol,2012,166(4):1411-1418.
  • 8陈燕佳,徐敏,金玮.动脉粥样硬化病变相关的内皮细胞衰老及抗衰老机制[J].国际心血管病杂志,2013,40(6):334-336. 被引量:5
  • 9何流漾,赵建中,戚春建.免疫细胞在动脉粥样硬化中的作用[J].国际心血管病杂志,2013,40(3):139-141. 被引量:15
  • 10Awojoodu AO,Ogle ME,SefcikLS,etal.Sphingosine1-phosphate receptor 3 regulates recruitment of antiinflammatory monocytes to microvessels during implantarteriogenesis[J].Proc NatlAcadSciU S A,2013,110(34):13785-13790.

二级参考文献60

  • 1Koenen RR, Weber C. Chemokines: established and noveltargets in atherosclerosis [J]. EMBO Mol Med, 2011,3(12); 713-725.
  • 2Kadi A, Meher AK* Sharma PR,et al. Identification of anovel macrophage phenotype that develops in response toatherogenic phospholipids via Nr.2 [ J Circ Res, 2010,107(6): 737-746.
  • 3Stoger JL, Gijbels MJ,van der Velden S,et al. Distributionof macrophage polarization markers in human atherosclerosis[J]. Atherosclerosis, 2012, 225(2) : 461-468.
  • 4Gui T, Shimokado A, Sun Y, et al. Diverse roles of macrophagesin atherosclerosis: from inflammatory biology to biomarkerdiscovery[J]. Mediators Inflamm, 2012,2012;693083.
  • 5Woollard KJ,Geissmann F. Monocytes in atherosclerosis :subsets and functions [J]. Nat Rev Cardiol, 2010,7(2):77-86.
  • 6Makinen PI, Lappalainen JP,Heinonen SE, et al. Silencingof either SR-A or CD36 reduces atherosclerosis inhyperlipidaemic mice and reveals reciprocal upregulation ofthese receptors[J]. Cardiovasc Res, 2010,88(3) : 530-538.
  • 7Little PJ,Chait A, Bobik A. Cellular and cytokine-basedinflammatory processes as novel therapeutic targets for theprevention and treatment of atherosclerosis [J]. PharmacolTher, 2011,131(3) : 255-268.
  • 8Businaro R, Tagliani A* Buttari B,et al. Cellular and molecularplayers in the atherosclerotic plaque progression^Jl. Ann NY Acad Sci, 2012,1262 : 134-141.
  • 9Go GW, Mani A. Low-density lipoprotein receptor (LDLR)family orchestrates cholesterol homeostasis [J]. Yale J BiolMed, 2012,85(1) : 19-28.
  • 10Moore KJ, Tabas I. Macrophages in the pathogenesis ofatherosclerosis[J]. Cell, 2011,145(3) : 341-355.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部